Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
5.71
+0.65 (12.85%)
At close: Nov 7, 2025, 4:00 PM EST
5.58
-0.13 (-2.28%)
After-hours: Nov 7, 2025, 7:32 PM EST
Alvotech Revenue
Alvotech had revenue of $173.34M in the quarter ending June 30, 2025, a decrease of -12.79%. This brings the company's revenue in the last twelve months to $562.48M, up 82.19% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$562.48M
Revenue Growth
+82.19%
P/S Ratio
2.89
Revenue / Employee
$555,808
Employees
1,012
Market Cap
1.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 491.98M | 398.60M | 426.84% |
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALVO News
- 1 day ago - Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO) - GlobeNewsWire
- 1 day ago - Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA - GlobeNewsWire
- 3 days ago - Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update - GlobeNewsWire
- 3 days ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November - Benzinga
- 4 days ago - Alvotech Shares Plunge 33% After FDA Flags Issues - Benzinga
- 5 days ago - Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 - GlobeNewsWire
- 16 days ago - Alvotech Announces Changes in Global Business Development and Commercial Operations Team - GlobeNewsWire
- 23 days ago - Alvotech: Promising Vertically Integrated Biosimilar Platform - Seeking Alpha